Last 11 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 21.35 | 13.72 | 13.30 | 14.40 | 14.91 | 12.91 | 26.24 | 13.97 | 26.74 | — | — | — |
| — | +6.3% | -49.3% | +3.1% | -44.3% | — | — | — | — | — | — | — | |
| P/S Ratio | 3.11 | 1.84 | 2.05 | 2.14 | 1.98 | 1.67 | 1.71 | 1.69 | 3.19 | — | — | — |
| — | +10.4% | +20.1% | +26.8% | -37.9% | — | — | — | — | — | — | — | |
| P/B Ratio | 2.10 | 2.55 | 2.75 | 2.94 | 2.71 | 2.28 | 2.27 | 2.34 | 2.24 | — | — | — |
| — | +11.8% | +21.0% | +25.4% | +20.7% | — | — | — | — | — | — | — | |
| P/FCF | 17.39 | 13.14 | 9.01 | 11.37 | — | — | — | — | 6.78 | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 15.03 | 8.08 | 9.17 | 9.93 | 11.26 | 8.54 | 12.24 | 9.54 | 19.05 | — | — | — |
| — | -5.3% | -25.1% | +4.1% | -40.9% | — | — | — | — | — | — | — | |
| EV / EBIT | 17.23 | 9.10 | 10.51 | 11.25 | 11.11 | 10.63 | 9.31 | 10.22 | 20.30 | — | — | — |
| — | -14.4% | +12.9% | +10.1% | -45.3% | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 63.3% | 66.0% | 65.0% | 64.5% | 61.4% | 63.8% | 57.5% | 61.9% | 62.9% | 61.4% | 62.5% | 60.8% |
| — | +3.5% | +13.2% | +4.3% | -2.4% | +3.9% | -8.1% | +1.8% | — | — | — | — | |
| Operating Margin | 21.9% | 23.8% | 22.7% | 22.0% | 19.0% | 20.2% | 15.4% | 19.9% | 19.7% | 17.7% | 20.4% | 14.7% |
| — | +18.0% | +47.5% | +10.4% | -3.2% | +14.0% | -24.5% | +35.3% | — | — | — | — | |
| Net Margin | 14.8% | 13.6% | 15.5% | 14.7% | 12.9% | 12.8% | 6.5% | 12.0% | 11.9% | 13.1% | 14.9% | 10.1% |
| — | +6.7% | +138.4% | +22.8% | +8.4% | -2.3% | -56.3% | +18.5% | — | — | — | — |
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 10.0% | 4.7% | 5.3% | 5.0% | 4.3% | 4.3% | 2.2% | 4.2% | 1.6% | 1.3% | 1.4% | 0.9% |
| — | +7.8% | +142.5% | +20.2% | +173.9% | +238.6% | +54.4% | +368.3% | — | — | — | — | |
| ROA | 4.9% | 2.4% | 2.7% | 2.4% | 2.1% | 2.2% | 1.1% | 2.0% | 0.9% | 0.9% | 1.1% | — |
| — | +9.8% | +150.4% | +22.4% | +144.7% | +149.3% | -1.4% | — | — | — | — | — | |
| ROIC | 7.6% | 4.3% | 3.9% | 3.8% | 3.2% | 3.4% | 2.5% | 3.3% | 1.4% | 1.1% | 1.4% | 1.0% |
| — | +23.6% | +57.2% | +15.0% | +134.6% | +210.0% | +77.0% | +242.2% | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.52 | 0.50 | 0.52 | 0.53 | 0.62 | 0.53 | 0.57 | 0.60 | 0.63 | 0.38 | 0.04 | — |
| — | -5.3% | -7.6% | -11.3% | -1.8% | +39.6% | +1410.4% | — | — | — | — | — | |
| Debt / EBITDA | 3.11 | 5.41 | 6.00 | 6.13 | 8.77 | 6.53 | 9.96 | 7.81 | 17.01 | 20.07 | 1.77 | — |
| — | -17.0% | -39.8% | -21.5% | -48.4% | -67.5% | +464.3% | — | — | — | — | — | |
| Current Ratio | 0.92 | 0.69 | 0.92 | 0.87 | 0.98 | 0.84 | 1.04 | 0.84 | 0.93 | 3.43 | 1.24 | — |
| — | -17.9% | -11.2% | +3.2% | +5.9% | -75.6% | -16.2% | — | — | — | — | — | |
| Quick Ratio | 0.71 | 0.52 | 0.71 | 0.63 | 0.78 | 0.58 | 0.73 | 0.54 | 0.62 | 3.16 | 1.01 | — |
| — | -10.7% | -2.8% | +16.8% | +25.6% | -81.7% | -27.6% | — | — | — | — | — | |
| Interest Coverage | 7.60 | 8.73 | 7.67 | 9.43 | 5.81 | 5.65 | 5.65 | 5.38 | 7.11 | 59.13 | 127.75 | — |
| — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 11 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HLN stock.
Haleon plc's current P/E is 21.3x. The average P/E over the last 4 quarters is 14.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Haleon plc's current operating margin is 21.9%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Haleon plc's business trajectory between earnings reports.